| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sarizotan | dopamine d2 receptor | small molecule | Successful target | TTD , drugbank , DGIDB | Schizophrenia[MeSHID:D012559] Schizoaffective Disorder[MeSHID:D011618] Parkinson Disease[MeSHID:D010300] Rett Syndrome[MeSHID:D015518] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.36 | investigational,phase 2/3 | partial agonist |
| sarizotan | dopamine d3 receptor | small molecule | NA | drugbank | Schizophrenia[MeSHID:D012559] Schizoaffective Disorder[MeSHID:D011618] Parkinson Disease[MeSHID:D010300] Rett Syndrome[MeSHID:D015518] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | investigational | ligand |
| sarizotan | 5-ht 1a receptor | NA | Successful target | TTD , DGIDB | Schizophrenia[MeSHID:D012559] Schizoaffective Disorder[MeSHID:D011618] Parkinson Disease[MeSHID:D010300] Rett Syndrome[MeSHID:D015518] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.91 | phase 2/3 | unknown |
| sarizotan | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank , DGIDB | Schizophrenia[MeSHID:D012559] Schizoaffective Disorder[MeSHID:D011618] Parkinson Disease[MeSHID:D010300] Rett Syndrome[MeSHID:D015518] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.91 | investigational | unknown |
| click here to return to the previous page | ||||||||